BLRX - BioLineRx: Investors Are About To Cash In On Motixafortide's Phase 3 Results

• BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology with 2 multi-indication candidates (Phase 3 and Phase 1/2a) and 1 approved product.
• BioLineRx's pipeline and products consist of one "off-strategy" legacy commercialized Class 2a medical device (BL-5010 for skin lesions) and two clinical-stage therapeutics run as combination therapies, Motixafortide (BL-8040) and AGI-134.
• BioLineRx is unique in its low-cost strategy with a cash burn expected at -$25M for 2020 and expected Jan. 21' cash of $50M after the Israeli ADR funds.
• BioLineRx's upcoming catalysts include Motixafortide's 1Q 2021 regulatory next steps announcement and AGI-134's 2H 2021 initial efficacy results for its Phase 1/2a for Metastatic Solid Tumors.
• In summary, the author projects BioLineRx Ltd. as a "buy" at a 2-3 year price target of $8.92 (+265% upside).

For further details see: